Advertisement
Screener

INNOVIVA, INC. (INVA) Other Revenue, Net (Deprecated 2018-01-31)

2.9 / 5 stars · 69/119 Roast Me

INNOVIVA, INC. Other Revenue, Net (Deprecated 2018-01-31)

INNOVIVA, INC. (INVA) reported Other Revenue, Net (Deprecated 2018-01-31) of $24.51 million for the 12-month period ending 2011-12-31, per its 10-K filed 2012-02-27.

Discontinued › Income Statement › Other Income

us-gaap:OtherSalesRevenueNet · last filed 2012-02-27

  • INNOVIVA, INC. other revenue, net (deprecated 2018-01-31) for the quarter ending 2011-12-31 was $5.36M, a 22.76% decline year-over-year.
  • INNOVIVA, INC. other revenue, net (deprecated 2018-01-31) for the quarter ending 2011-09-30 was $6.43M, a 21.29% increase year-over-year.
  • INNOVIVA, INC. other revenue, net (deprecated 2018-01-31) for the quarter ending 2011-06-30 was $6.39M, a 2.00% increase year-over-year.
  • INNOVIVA, INC. other revenue, net (deprecated 2018-01-31) for the quarter ending 2011-03-31 was $6.33M.
  • INNOVIVA, INC. other revenue, net (deprecated 2018-01-31) for fiscal 2011 was $24.51M, a 1.19% increase from fiscal 2010.
  • INNOVIVA, INC. other revenue, net (deprecated 2018-01-31) for fiscal 2010 was $24.22M, a 0.62% decline from fiscal 2009.
  • INNOVIVA, INC. other revenue, net (deprecated 2018-01-31) for fiscal 2009 was $24.37M.
Period endOther Revenue, Net (Deprecated 2018-01-31) 3 monthOther Revenue, Net (Deprecated 2018-01-31) 6 monthOther Revenue, Net (Deprecated 2018-01-31) 9 monthOther Revenue, Net (Deprecated 2018-01-31) 12 month
2011-12-31$5.36M
derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-27
$11.79M
derived: sum of 2 quarters · filed 2012-02-27
$18.18M
derived: sum of 3 quarters · filed 2012-02-27
$24.51M
10-K · filed 2012-02-27
2011-09-30$6.43M
10-Q · filed 2011-11-02
$12.82M
derived: sum of 2 quarters · filed 2011-11-02
$19.15M
10-Q · filed 2011-11-02
$26.09M
derived: sum of 4 quarters · filed 2012-02-27
2011-06-30$6.39M
10-Q · filed 2011-08-03
$12.72M
10-Q · filed 2011-08-03
$19.66M
derived: sum of 3 quarters · filed 2012-02-27
$24.96M
derived: sum of 4 quarters · filed 2012-02-27
2011-03-31$6.33M
derived: 10-K 12 month − 3 quarters · filed 2012-02-27
$13.27M
derived: sum of 2 quarters · filed 2012-02-27
$18.57M
derived: sum of 3 quarters · filed 2012-02-27
$24.84M
derived: sum of 4 quarters · filed 2012-02-27
2010-12-31$6.94M
derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-27
$12.24M
derived: sum of 2 quarters · filed 2012-02-27
$18.51M
derived: sum of 3 quarters · filed 2012-02-27
$24.22M
10-K · filed 2012-02-27
2010-09-30$5.30M
10-Q · filed 2011-11-02
$11.57M
derived: sum of 2 quarters · filed 2011-11-02
$17.28M
10-Q · filed 2011-11-02
2010-06-30$6.26M
10-Q · filed 2011-08-03
$11.98M
10-Q · filed 2011-08-03
2009-12-31$24.37M
10-K · filed 2012-02-27

Similar stocks

Stock NameCountryMarket CapPE Ratio
ArriVent BioPharma, Inc. (AVBP)United States$1.485B-10.25
Ultragenyx Pharmaceutical Inc. (RARE)United States$1.456B-5.62
OMEROS CORP (OMER)United States$1.456B5.50
ANAPTYSBIO, INC (ANAB)United States$1.546B-60.20
Kailera Therapeutics, Inc. (KLRA)United States$1.552B
Syndax Pharmaceuticals Inc (SNDX)United States$1.606B-8.82
Oric Pharmaceuticals, Inc. (ORIC)United States$1.367B-8.00
Rapport Therapeutics, Inc. (RAPP)United States$1.623B-14.56
Stoke Therapeutics, Inc. (STOK)United States$1.630B-9.82
Xeris Biopharma Holdings, Inc. (XERS)United States$1.632B-80.10